MBX Biosciences reports FY2024 net loss of $61.9M; pipeline milestones for 2025

MBX Biosciences, Inc.

Cash and marketable securities $262.1M as of Dec 31, 2024; expected to fund operations into mid-2027.
Phase 2 Avail trial of canvuparatide in hypoparathyroidism fully enrolled (64 patients); topline results expected Q3 2025.
MBX 1416 Phase 1 trial positive; Phase 2 in post-bariatric hypoglycemia to start 2H 2025.
IND submission for MBX 4291 in obesity anticipated in Q2 2025.
Net loss for FY2024 was $61.9M vs $32.6M in FY2023, driven by increased R&D and G&A costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.